Literature DB >> 34803572

Improvement of Blood Processing and Safety by Automation and Pathogen Reduction Technology.

Ana Isabel Pérez Aliaga1, Gorka Labata2, Alfonso Aranda1, Marcia Cardoso3, Fernando Puente1, José María Domingo1, Carmen Garcés1.   

Abstract

INTRODUCTION: The objective of the present study was to describe the experience of the Blood and Tissues Bank of Aragon with the Reveos® Automated Blood Processing System and Mirasol® Pathogen Reduction Technology (PRT) System, comparing retrospectively routine quality data obtained in two different observation periods.
METHODS: Comparing quality data encompassing 6,525 blood components from the period 2007-2012, when the semi-automated buffy coat method was used in routine, with 6,553 quality data from the period 2014-2019, when the Reveos system and subsequently the Mirasol system were implemented in routine.
RESULTS: Moving from buffy coat to Reveos led to decreased discard rates of whole blood units (1.2 to 0.1%), increased hemoglobin content (48.1 ± 7.6 to 55.4 ± 6.6 g/unit), and hematocrit (58.9 ± 6.5% to 60.0 ± 4.9%) in red blood cell concentrates. Platelet concentrates (PCs) in both periods had similar yields (3.5 ×1011). Whereas in the earlier period, PCs resulted from pooling 5 buffy coats, in the second period 25% of PCs were prepared from 4 interim platelet units. The mean level of factor VIII in plasma was significantly higher with Reveos (92.8 vs. 97.3 IU). Mirasol PRT treatment of PCs reduced expiry rates to 1.2% in 2019. One septic transmission was reported with a non-PRT treated PCs, but none with PRT-treated PCs.
CONCLUSION: Automation contributed to standardization, efficiency, and improvement of blood processing. Released resources enabled the effortless implementation of PRT. The combination of both technologies guaranteed the self-sufficiency and improvement of blood safety.
Copyright © 2021 by S. Karger AG, Basel.

Entities:  

Keywords:  Automation; Blood processing; Pathogen reduction technology; Safety

Year:  2021        PMID: 34803572      PMCID: PMC8578802          DOI: 10.1159/000516696

Source DB:  PubMed          Journal:  Transfus Med Hemother        ISSN: 1660-3796            Impact factor:   3.747


  23 in total

1.  Blood component fractionation: manual versus automatic procedures.

Authors:  Daniela Pasqualetti; Alessandro Ghirardini; Maria Cristina Arista; Stefania Vaglio; Azis Fakeri; Alan A Waldman; Gabriella Girelli
Journal:  Transfus Apher Sci       Date:  2004-02       Impact factor: 1.764

2.  Platelet concentrates produced from whole blood using the Atreus processing system.

Authors:  S Thomas; M Beard; M Garwood; M Callaert; R Cardigan
Journal:  Vox Sang       Date:  2009-04-09       Impact factor: 2.144

3.  Counting platelets in platelet concentrates on hematology analyzers: a multicenter comparative study.

Authors:  Pieter F van der Meer; Margriet J Dijkstra-Tiekstra; Anne Mahon; Janny de Wildt-Eggen
Journal:  Transfusion       Date:  2008-10-02       Impact factor: 3.157

4.  Evaluation of the quality of blood components prepared using the Reveos automated blood processing system.

Authors:  L Johnson; K M Winter; M Kwok; S Reid; D C Marks
Journal:  Vox Sang       Date:  2013-05-28       Impact factor: 2.144

Review 5.  Improving the safety of whole blood-derived transfusion products with a riboflavin-based pathogen reduction technology.

Authors:  Susan Yonemura; Suzann Doane; Shawn Keil; Raymond Goodrich; Heather Pidcoke; Marcia Cardoso
Journal:  Blood Transfus       Date:  2017-05-11       Impact factor: 3.443

Review 6.  Automation of blood component preparation from whole blood collections.

Authors:  J Cid; L Magnano; M Lozano
Journal:  Vox Sang       Date:  2014-01-22       Impact factor: 2.144

7.  Impact of implementing pathogen reduction technologies for platelets on reducing outdates.

Authors:  Carlos Gorria; Gorka Labata; Mikel Lezaun; F Javier López; Ana Isabel Pérez Aliaga; Miguel Ángel Pérez Vaquero
Journal:  Vox Sang       Date:  2019-11-14       Impact factor: 2.144

8.  Dose of prophylactic platelet transfusions and prevention of hemorrhage.

Authors:  Sherrill J Slichter; Richard M Kaufman; Susan F Assmann; Jeffrey McCullough; Darrell J Triulzi; Ronald G Strauss; Terry B Gernsheimer; Paul M Ness; Mark E Brecher; Cassandra D Josephson; Barbara A Konkle; Robert D Woodson; Thomas L Ortel; Christopher D Hillyer; Donna L Skerrett; Keith R McCrae; Steven R Sloan; Lynne Uhl; James N George; Victor M Aquino; Catherine S Manno; Janice G McFarland; John R Hess; Cindy Leissinger; Suzanne Granger
Journal:  N Engl J Med       Date:  2010-02-18       Impact factor: 91.245

Review 9.  Buffy-coat-derived pooled platelet concentrates and apheresis platelet concentrates: which product type should be preferred?

Authors:  H Schrezenmeier; E Seifried
Journal:  Vox Sang       Date:  2009-01-04       Impact factor: 2.144

Review 10.  Why has demand for platelet components increased? A review.

Authors:  L J Estcourt
Journal:  Transfus Med       Date:  2014-10       Impact factor: 2.019

View more
  1 in total

1.  Assessing quality of blood components derived from whole blood treated with riboflavin and ultraviolet light and separated with a fully automated device.

Authors:  Michał Bubiński; Agnieszka Gronowska; Paweł Szykuła; Agnieszka Woźniak; Aleksandra Rodacka; Scott Santi; Marcia Cardoso; Elżbieta Lachert
Journal:  Blood Transfus       Date:  2022-02-01       Impact factor: 5.752

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.